Cost-effectiveness of screening for coronary artery disease in asymptomatic patients with Type 2 diabetes and additional atherogenic risk factors
about
Cost-effective diagnostic cardiovascular imaging: when does it provide good value for the money?Stress echocardiography with contrast for the diagnosis of coronary artery disease: an evidence-based analysis.Screening for coronary artery disease in patients with type 2 diabetes mellitus: An evidence-based reviewCost-effectiveness of follow-up of pulmonary nodules incidentally detected on cardiac computed tomographic angiography in patients with suspected coronary artery disease.64-slice computed tomographic angiography for the diagnosis of intermediate risk coronary artery disease: an evidence-based analysis.Cardiac magnetic resonance imaging for the diagnosis of coronary artery disease: an evidence-based analysis.Myocardial perfusion imaging for evaluation of suspected ischemia and its relationship with glycemic control in South African subjects with diabetes mellitusSingle photon emission computed tomography for the diagnosis of coronary artery disease: an evidence-based analysis.Stress echocardiography for the diagnosis of coronary artery disease: an evidence-based analysis.Cost-effectiveness analysis of coronary artery disease screening in HIV-infected men.Cost-effectiveness of initial stress cardiovascular MR, stress SPECT or stress echocardiography as a gate-keeper test, compared with upfront invasive coronary angiography in the investigation and management of patients with stable chest pain: mid-teStrategies to curb the epidemic of diabetes and obesity in primary care settingsDiagnosis of coronary artery disease in persons with diabetes mellitus.The German Coronary Artery Disease Risk Screening Model: development, validation, and application of a decision-analytic model for coronary artery disease prevention with statins.
P2860
Q24628790-1D98922B-2443-4D8F-9B1C-582CD6287F67Q30462647-2B8689AB-37A1-408A-B91B-4583F701D0E8Q30471287-040948DE-DA8F-41C3-B641-918BDB780984Q34071153-2C0CE528-95BD-4F29-B64E-EB6FE3888C6BQ34449166-DBD1624A-379D-44C1-9501-3F2013491AA3Q34449172-21E15210-DBDC-4A56-9B38-48A45A50D9ABQ34548323-F0C9AEFF-9EAB-4A9B-92A1-FF17B319C163Q36040130-477BE13A-A792-41D0-90D6-575D7C077F03Q36040187-9B123D24-DBF9-4BE7-92A2-9929DF42F369Q37344531-23B248EB-2555-468B-A9F0-78F444584CCDQ37572029-8F0C8F12-F26E-47B1-AAA5-04BCC58B5017Q42357082-FECA8780-2E70-4BF5-BC11-166BD12557AEQ46099347-812B2F84-7D25-4C03-9200-BAF917AB99C0Q51791173-439720AF-7CBB-4B25-BD24-04097642F572
P2860
Cost-effectiveness of screening for coronary artery disease in asymptomatic patients with Type 2 diabetes and additional atherogenic risk factors
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Cost-effectiveness of screenin ...... ional atherogenic risk factors
@ast
Cost-effectiveness of screenin ...... ional atherogenic risk factors
@en
Cost-effectiveness of screenin ...... ional atherogenic risk factors
@nl
type
label
Cost-effectiveness of screenin ...... ional atherogenic risk factors
@ast
Cost-effectiveness of screenin ...... ional atherogenic risk factors
@en
Cost-effectiveness of screenin ...... ional atherogenic risk factors
@nl
prefLabel
Cost-effectiveness of screenin ...... ional atherogenic risk factors
@ast
Cost-effectiveness of screenin ...... ional atherogenic risk factors
@en
Cost-effectiveness of screenin ...... ional atherogenic risk factors
@nl
P2093
P2860
P1476
Cost-effectiveness of screenin ...... ional atherogenic risk factors
@en
P2093
Kenji Maeda
Sizuko Nagata-Kobayashi
Takeshi Morimoto
Takuro Shimbo
Tsuguya Fukui
Yasuaki Hayashino
P2860
P304
P356
10.1111/J.1525-1497.2004.40012.X
P577
2004-12-01T00:00:00Z
P5875
P6179
1035730305